Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Other peptide-based medications are widely used for conditions like diabetes, multiple sclerosis, and cancer
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
2024 review of 36 studies (1993-2024) confirms extensive preclinical research but no approved clinical applications
Injections can cause minor effects such as irritation or itching at the injection site, and the consumer fact sheet is a good plain-language reference on what B12 does and does not do
US$ 26.57
US$ 22.35
US$ 20.89
US$ 26.38
US$ 20.43
US$ 24.61
